{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-179048","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.865638+00:00","generated_at":"2026-05-15T03:54:01.311146+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW","bullets":["100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.","Primary composite endpoint (virologic response + ALT normalization) reached by 45% and 35% vs 0% control (p=0.003, 0.024).","Brelovitug was well tolerated; no discontinuations, low grade 3+ events, no related serious AEs.","Full Phase 2b results to be presented at EASL Congress May 27-30, 2026.","Phase 3 topline data from AZURE-1/4 expected H2 2026; potential U.S. BLA submission in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179048","json":"https://secwatch.observer/filing/0001193125-26-179048.json","markdown":"https://secwatch.observer/filing/0001193125-26-179048.md","text":"https://secwatch.observer/filing/0001193125-26-179048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526179048/0001193125-26-179048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312526179048/d116875d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:54:01.311146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}